KEY PUBLICATIONS DISCUSSED IN THIS PROGRAM

Burger RA et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25(33):5165-71.Abstract.

Coleman RL et al. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 2007;12(1):72-8. Abstract

Ferrandina G et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26(6):890-6. Abstract

Gordon AN et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22. Abstract

Han ES et al. Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study. Proc ASCO 2007;Abstract 21021.

Konner JA et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and IV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. Proc ASCO 2007;Abstract 5523.

Markman M et al. Phase II trial of weekly paclitaxel (80 mg/m²) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study. Gynecol Oncol 2006;101(3):436-40. Abstract

Orlando M et al. Randomized trials of combination chemotherapy (combo) versus monotherapy (mono) in relapsed ovarian carcinoma (ROC): A meta-analysis of published data. Proc ASCO 2007;Abstract 5524.

Pfisterer J et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTCGCG. J Clin Oncol 2006;24(29):4699-707. Abstract

Wright JD et al. A multi-institutional evaluation of the safety and efficacy of bevacizumab for recurrent, platinum-resistant ovarian cancer. Proc ASCO 2006;Abstract 5019.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Armstrong — Advisory Committee: Bayer Pharmaceuticals Corporation, Biogen Idec, Cephalon Inc, Genentech BioOncology, Onyx Pharmaceuticals Inc. Dr Spriggs — Advisory Committee: Abraxis BioScience, Merck and Company Inc, Ortho Biotech Products LP; Consulting Agreements: Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, Roche Laboratories Inc; Data Safety and Monitoring Board: GlaxoSmithKline; Paid Research: Eli Lilly and Company, Genentech BioOncology. Dr Coleman — Consulting Agreements: Abraxis BioScience, Eli Lilly and Company, Genentech BioOncology, GlaxoSmithKline, Ortho Biotech Products LP; Paid Research: Abraxis BioScience; Speakers Bureau: Eli Lilly and Company, GlaxoSmithKline, Ortho Biotech Products LP.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Home

EDITOR
Neil Love, MD

INTERVIEWS
Deborah K Armstrong, MD
- Select publications

David R Spriggs, MD
- Select publications

Robert L Coleman, MD
- Select publications

Ovarian Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office